Harmony Biosciences Sees Unprecedented Growth
WAKIX (pitolisant) Net Revenue of $186.0 million for Third Quarter 2024; Surpassed $2 Billion in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA for Pitolisant in Idiopathic Hypersomnia (IH) in the Coming Quarter
Next-Gen Pitolisant-GR and Pitolisant-HD Programs Advance; IND for Novel Orexin-2 Agonist On Track for Mid-2025
Advanced Development Program for EPX-100 in Rare Epilepsies; Phase 3 Trial in Dravet Syndrome Ongoing
Key Financial Highlights For Q3 2024
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) achieved a milestone by reporting a record net revenue of $186.0 million for the quarter ending September 30, 2024. This impressive feat pushes the company past the $2 billion mark in cumulative net revenue for its flagship product, WAKIX, launched in 2019, underscoring the product's significant market impact in the treatment of narcolepsy.
The notable financial performance reflects sustained demand for WAKIX, driven by its effectiveness and the expanding understanding of narcolepsy's complexities among healthcare professionals. Throughout Q3 2024, the average patient count utilizing WAKIX increased to approximately 6,800, marking a notable growth trajectory as the company targets a broader market with around 80,000 diagnosed narcolepsy cases in the U.S.
Forward-Looking Initiatives and Product Development Pipeline
As part of its ongoing commitment to innovation, Harmony plans to submit a supplemental new drug application (sNDA) for pitolisant aimed at treating idiopathic hypersomnia. This decision is guided by promising data from recent long-term studies showcasing the drug's sustained efficacy in patient care.
In addition, the company is advancing its next-generation formulations, aiming to enhance the efficacy and broaden the applications of pitolisant and associated programs. The pitolisant-HD program, designed for higher doses with optimized pharmacokinetics, is being developed with a view to maximize therapeutic benefit for narcolepsy patients. Furthermore, the innovative Orexin-2 agonist program is on track for Investigational New Drug (IND) application submission by mid-2025, extending Harmony’s leadership position in the sleep/wake disorder domain.
Development in Rare Neurological Disorders
Harmony is equally committed to addressing the needs of patients with rare neurological conditions. The company is making strides with its program for EPX-100, targeting individuals suffering from developmental epileptic encephalopathies. The ongoing Phase 3 clinical trials for EPX-100 in Dravet syndrome are projected to yield topline data in 2026, promising to fill significant treatment gaps in this area.
Moreover, preparations are in progress to initiate Phase 3 trials for Lennox-Gastaut syndrome, further enhancing Harmony's robust pipeline designed to tackle serious and complex neurological issues that often lack effective treatment options.
Financial Outlook and Strategic Guidance
Looking ahead, Harmony has reiterated its guidance for full-year 2024 net product revenue in the range of $700 million to $720 million. This optimistic forecast is buoyed by the success of WAKIX and the ongoing expansion of its therapeutic offerings.
The company's commitment to optimizing its operational efficiency while maintaining a focus on strategic growth is evident in its projected trajectory, which remains strong, suggesting the potential for over $3 billion in future net revenues as new products come to market.
Frequently Asked Questions
What were Harmony Biosciences' key financial achievements in Q3 2024?
Harmony reported a record net revenue of $186 million, marking significant growth and surpassing $2 billion in cumulative revenue since the launch of WAKIX.
What future developments are planned for Harmony's product pipeline?
The company intends to submit a supplemental NDA for pitolisant in idiopathic hypersomnia and is developing a novel Orexin-2 agonist, further expanding treatment options for Central Nervous System disorders.
How many patients are currently using WAKIX?
As of Q3 2024, approximately 6,800 patients are utilizing WAKIX, reflecting a steady increase in patient access and acceptance.
What initiatives does Harmony have for addressing rare neurological disorders?
Harmony is advancing its EPX-100 program for Dravet syndrome and plans to begin trials for Lennox-Gastaut syndrome, which addresses pivotal needs in rare epilepsy treatment.
What is Harmony's revenue guidance for 2024?
Harmony anticipates full-year net product revenues in the range of $700 million to $720 million, highlighting its robust growth strategy.
